San­thera en­ters li­cense agree­ment with Chiesi Group; Tonix's co­caine in­tox­i­ca­tion drug, Io­vance's cer­vi­cal can­cer treat­ment win FDA's break­through sta­tus

→ Swiss-based San­thera has en­tered an ex­clu­sive glob­al — ex­cept for the US and Cana­da— li­cense agree­ment with in­ter­na­tion­al re­search-fo­cused health­care group Chiesi Far­ma­ceu­ti­ci. The com­pa­ny says that Chiesi Group will in-li­cense Rax­one for the treat­ment of LHON for a to­tal con­sid­er­a­tion of CHF 105 mil­lion (about $104 mil­lion), and this will con­sti­tute an up­front of about $49.5 mil­lion and near-to mid-term sales mile­stone pay­ments of up to about $54.5 mil­lion. Fol­low­ing the com­ple­tion of “cer­tain re­im­burse­ment and post-reg­u­la­to­ry com­mit­ments on the part of San­thera,” Chiesi Group will have the op­tion to ful­ly ac­quire San­thera’s Rax­one busi­ness.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.